Market capitalization | $330.87m |
Enterprise Value | $128.92m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 0.90 |
P/S ratio (TTM) P/S ratio | 2.30 |
P/B ratio (TTM) P/B ratio | 1.42 |
Revenue growth (TTM) Revenue growth | 15.43% |
Revenue (TTM) Revenue | $143.68m |
As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.
11 Analysts have issued a Arcturus Therapeutics Ltd forecast:
11 Analysts have issued a Arcturus Therapeutics Ltd forecast:
Mar '25 |
+/-
%
|
||
Revenue | 144 144 |
15%
15%
|
|
Gross Profit | - - |
-
|
|
EBITDA | -79 -79 |
35%
35%
|
EBIT (Operating Income) EBIT | -82 -82 |
33%
33%
|
Net Profit | -68 -68 |
36%
36%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Arcturus Therapeutics Holdings, Inc. engages in the research and development of medical applications for the nucleic acid-focused technology. The firm develops RNA therapeutics which focuses on the treatment of liver and respiratory diseases. Its pipeline include LUNAR-OTC and LUNAR CF. The company was founded in 2013 and is headquartered in San Diego, CA.
Head office | Israel |
CEO | Joseph Payne |
Employees | 175 |
Founded | 2013 |
Website | arcturusrx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.